TrialJAMA oncology2017

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.

Eric Hahnen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.